Skip to content
Search

Latest Stories

Asda urgently recalls sandwich filler over wrong use-by date warning

The warning follows growing concern after Asda recalls sandwich filler products in previous months

asda recalls sandwich filler

Notices are being displayed in all Asda stores

Getty

Asda has issued a product recall for one of its ready-to-eat meat items due to an incorrect use-by date, sparking a food safety warning from the Food Standards Agency (FSA).

The recall applies to Asda hot and spicy chicken breast slices, sold in 160g packs, which have been mistakenly labelled with a use-by date of 30 May 2024. Customers are being advised not to eat the product and to return it to their nearest store for a full refund.


The FSA said: “If you have bought the above product, do not eat it. Instead, return it to your nearest store for a refund.” No receipt is required to claim the refund.

Although the issue relates specifically to chicken, the warning follows growing concern after Asda recalls sandwich filler products in previous months, highlighting ongoing vigilance in monitoring pre-packed chilled foods.

Asda issued an apology, stating: “If you have purchased Asda hot and spicy chicken breast slices with a use by date of 30 May, please bring it back to your nearest store where you will be given a full refund. You do not need your receipt. We are very sorry for any inconvenience caused.”

Notices are being displayed in all Asda stores where the affected product was sold. These inform customers of the reason behind the recall and what action to take if they have already purchased the item.

Food recall notices are issued when there is a potential risk to consumers, and the FSA regularly updates its list of recalled products to ensure public safety.

Customers are urged to check their fridges and dispose of the product if affected.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less